HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tolero Pharmaceuticals Inc.

Division of Sumitomo Chemical Co.
toleropharmaceuticals.com

Latest From Tolero Pharmaceuticals Inc.

M&A A Major Pillar Of Sumitomo Dainippon's New Mid-Term Plan

Mid-size Japanese player Sumitomo Dainippon sets aside billions for potential M&A deals under a new business plan designed to fill gaps in its neurology pipeline as it prepares to lose exclusivity for its top global product.

Business Strategies M & A

Gottlieb Wants Timely Approval Of User Fee Bill, Balanced LDT Plan

FDA Commissioner-nominee Scott Gottlieb was approved by the Senate HELP committee April 27, sending his confirmation to the full Senate. Written responses from Gottlieb to senators' questions provided in advance of the vote don't hold any big surprises, but they provide a view into priorities of the incoming official and the lawmakers, including quick user-fee reauthorization, resolving the lab-developed test oversight debate, off-label and "right-to-try" issues and post-market surveillance.

Policy Leadership

Gottlieb Confirmation: Scheduling, Paperwork Delay Committee Vote One Day

FDA Commissioner nominee's answers to questions about his confidential committee paperwork did not arrive until minutes before the committee hearing, but Republicans' scheduling conflicts also may be to blame for the delay.

FDA Leadership

Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda

First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sumitomo Chemical Co.
  • Senior Management
  • David J Bearss, PhD, CEO
    David W Sampson, CFO
    Steven L Warner, PhD, VP, Drug Discovery & Dev.
    Michael V McCullar, PhD, COO
  • Contact Info
  • Tolero Pharmaceuticals Inc.
    Phone: (801) 769-0796
    3900 N Traverse Mountain Blvd, Ste. 100
    Lehi, UT 84043
    USA
UsernamePublicRestriction

Register